Protego Biopharma
PrivateLast Round
Series B
Dec 1, 2025
Total Funding Raised
$181M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Protego Biopharma is a biotechnology company that develops a small molecule therapeutics platform aimed at reprogramming protein folding to treat systemic amyloid diseases and other protein misfolding disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Protego Biopharma Comparables
Compare Protego Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vicinitas Therapeutics | 81% | |
| Congruence Therapeutics | 80% | |
| Gain Therapeutics Inc | 78% |
Protego Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 1, 2025 | ||||
| Series A | Nov 17, 2021 |
Key People
Founding team and executive leadership
Protego Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Seed, Series A |
| Omega Funds | Series B |
| Forbion | Series B |
| Digitalis Ventures | Series B |
| Vida Ventures | Series B, Series A |
| MPM BioImpact | Series B |
| Droia Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2026
Lead AL amyloidosis program advances to Phase III registrational trial.
- Apr 27, 2026
Open roles increased to 12, representing 50% of headcount.
Protego Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Protego Biopharma's valuation, stock price, and market status.
Is Protego Biopharma a public or private company?
Protego Biopharma is a private company.
What is the current stock price of Protego Biopharma?
Protego Biopharma is a private company with no public stock price. No recent secondary market data is available.
How much is Protego Biopharma worth (valuation)?
Valuation information for Protego Biopharma is not publicly available.
Can I buy Protego Biopharma stock?
Protego Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Protego Biopharma's last funding round?
Protego Biopharma's most recent funding round was Series B on December 1, 2025.
Who are the main investors in Protego Biopharma?
Key investors in Protego Biopharma include MPM Capital, Forbion, Vida Ventures, Lightspeed Venture Partners.
Will Protego Biopharma IPO soon?
No public IPO plans have been announced for Protego Biopharma.
How can I track Protego Biopharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Protego Biopharma's secondary market activity and sign up for updates.